Cargando…
HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic
High-density lipoprotein (HDL) have long been studied for their protective role against cardiovascular diseases, however recently relationship between HDL and cancer came into focus. Several epidemiological studies have shown an inverse correlation between HDL-cholesterol (HDL-C) and cancer risk, an...
Autores principales: | Morin, Emily E., Li, Xiang-An, Schwendeman, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283888/ https://www.ncbi.nlm.nih.gov/pubmed/30555417 http://dx.doi.org/10.3389/fendo.2018.00715 |
Ejemplares similares
-
HDL in sepsis – risk factor and therapeutic approach
por: Morin, Emily E., et al.
Publicado: (2015) -
Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers
por: Ha, Siyoung, et al.
Publicado: (2023) -
Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020) -
High levels of oxidized fatty acids in HDL impair the antioxidant function of HDL in patients with diabetes
por: Feng, Juan, et al.
Publicado: (2022) -
HDL as a Biomarker, Potential Therapeutic Target, and Therapy
por: Navab, Mohamad, et al.
Publicado: (2009)